Table 1.
Demographic and clinical characteristics of the study population (n = 515)
| Variables | Percent (N) |
|---|---|
| Age (years) | 83.8 ± 3.4 |
| 80 ≃ 85 | 63.5% (327) |
| 85 ≃ 90 | 29.5% (152) |
| ≥ 90 | 7% (36) |
| Sex | |
| Male | 79.6% (410) |
| Female | 20.4% (105) |
| Hepatitis B | |
| Yes | 4.3% (22) |
| No | 95.7% (493) |
| Fatty liver | |
| Yes | 9.1% (47) |
| No | 90.9% (468) |
| Biliary calculus | |
| Yes | 17.1% (88) |
| No | 82.9% (427) |
| Other diseasesa | |
| ≤ 2 | 6% (31) |
| 3 ≃ 5 | 41.2% (212) |
| ≥ 5 | 52.8% (272) |
| Other drugsb | |
| < 5 | 19.2% (99) |
| 5 ≃ 10 | 71.5% (368) |
| ≥ 10 | 9.3% (48) |
| Drinking habitsc | |
| No drinking | 95.3% (491) |
| Mild to moderate | 2.7% (14) |
| Heavy | 1.9% (10) |
| Statin variety | |
| Simvastatin | 19.1% (98) |
| Fluvastatin | 22.5% (116) |
| Pravastatin | 15.5% (80) |
| Rosuvastatin | 16.5% (85) |
| Atorvastatin | 26.4% (136) |
| Statin dose | |
| Low | 13.6% (70) |
| Standard | 86.4% (445) |
aIncluding hypertension, diabetes, cerebral infarction, atrial fibrillation, chronic bronchitis, chronic obstructive pulmonary disease, chronic gastritis, osteoporosis, benign prostatic hyperplasia, and biliary calculus
bIncluding antihypertensive agents, antidiabetic agents, clopidogrel, aspirin, beta-blockers, isosorbide mononitrate, trimetazidine, citicoline, cilostazol, warfarin, digoxin, ambroxol, aminophylline, rebamipide, rabeprazole, calcitriol, calcium carbonate, oral bisphosphonates, finasteride, tamsulosin, and digestive enzymes
cNo drinking: not drinking in a previous year; light drinkers: current use of 3 drinks per week; moderate drinkers: current use of 3 to 7 drinks per week for women, and 3 to 14 drinks per week for men; heavy drinkers: current use of more than 7 drinks per week for women and 14 drinks per week for men